Compare HCC & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCC | ZLAB |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.0B |
| IPO Year | 2017 | 2017 |
| Metric | HCC | ZLAB |
|---|---|---|
| Price | $88.10 | $17.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $74.50 | $57.22 |
| AVG Volume (30 Days) | 786.1K | ★ 1.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $1,224,320,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $30.20 |
| Revenue Next Year | $46.92 | $34.71 |
| P/E Ratio | $130.69 | ★ N/A |
| Revenue Growth | N/A | ★ 24.14 |
| 52 Week Low | $38.00 | $16.82 |
| 52 Week High | $89.06 | $44.34 |
| Indicator | HCC | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 70.04 | 31.02 |
| Support Level | $78.00 | $16.82 |
| Resistance Level | $85.40 | $18.67 |
| Average True Range (ATR) | 3.42 | 0.60 |
| MACD | 0.26 | 0.13 |
| Stochastic Oscillator | 88.92 | 33.24 |
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.